Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$237.17 USD
-0.29 (-0.12%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $237.10 -0.07 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$237.17 USD
-0.29 (-0.12%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $237.10 -0.07 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
Zacks News
Becton Dickinson (BDX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.30% and 0.34%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Nov 5: BDX, ZBH & More
by Urmimala Biswas
Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.
Can BD Medical Drive Becton, Dickinson's (BDX) Q4 Earnings?
by Zacks Equity Research
Headwinds in the DCB business and unfavorable foreign exchange rates might have partially impacted Becton, Dickinson's (BDX) fiscal Q4 performance.
Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Dental Supplies Industry's Near-Term Outlook Looks Bright
by Sreyoshi Mukherjee
With popular trends of digital dentistry and robotics gaining momentum, near-term prospects of the dental industry look promising.
Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit
by Zacks Equity Research
Following the acquisition closure of GlaxoSmithKline's plant, Thermo Fisher (TMO) will continue to manufacture APIs for the same under a multi-year supply agreement.
Cybersecurity a Top Priority for Healthcare: 3 Stocks to Watch
by Sreyoshi Mukherjee
As cybersecurity is the need of the hour for U.S. healthcare companies, let's keep an eye on three stocks.
Why Is Becton Dickinson (BDX) Up 4.1% Since Last Earnings Report?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Estee Lauder, Becton, Dickinson, Applied Materials, Regeneron and HollyFrontier
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Estee Lauder, Becton, Dickinson, Applied Materials, Regeneron and HollyFrontier
Top Analyst Reports for Estee Lauder, Becton, Dickinson & Applied Materials
by Mark Vickery
Today's Research Daily features updated research reports on 16 major stocks, including Estee Lauder (EL), Becton, Dickinson (BDX) and Applied Materials (AMAT).
Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
FDA Resets PAD Guidelines: The Road Ahead for Device Makers
by Urmimala Biswas
On its advisory list, the FDA suggests that doctors should point out the risks and benefits of all available PAD treatment options to their patients.
Cardiovascular Systems Set to Present LIBERTY 360 Outcome
by Zacks Equity Research
This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).
China Arrests Yuan's Plunge. Will Markets Gain?
by Zacks Equity Research
China Arrests Yuan's Plunge. Will Markets Gain?
Stock Market News For Aug 6, 2019
by Zacks Equity Research
Benchmarks fell to their lowest levels for the year on Monday.
Index Futures Rebound as China Arrests Yuan Plunge
by Zacks Equity Research
U.S. stock index futures rebounded strongly ahead of trading on Tuesday after Chinese authorities acted to arrest the yuan???s decline.
Becton, Dickinson (BDX) Beats on Q3 Earnings and Revenues
by Zacks Equity Research
Strong contributions from BD Medical and Interventional units drive Becton, Dickinson???s (BDX) fiscal third quarter.
Becton Dickinson (BDX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.98% and 0.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Becton, Dickinson (BDX) Ahead of Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) expects to gain from core segmental strength in the third quarter.
Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) projects operating income within $460-$465 million for the second quarter.
IVD Market Sustains Momentum: 3 Stocks in Focus
by Trina Mukherjee
In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.
Top Research Reports for Adobe, Charter Communications & HCA Healthcare
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Adobe (ADBE), Charter Communications (CHTR) and HCA Healthcare (HCA).